Adult urologyEffect of yohimbine-trazodone on psychogenic impotence: A randomized, double-blind, placebo-controlled study
References (13)
Psychologic factors in the multidisciplinary evaluation and treatment of erectile dysfunction
Urol Clin North Am
(1988)- et al.
Effect of yohimbine hydrochloride, onerectile impotence: a double-blind study
J Urol
(1989) - et al.
Effects of fenfluramine, m-chlorophenylpiperazine, and other related agonists and antagonists on penile erections in non-human primates
Life Sci
(1988) - et al.
Double-blind trial of yohimbine in treatment of psychogenic impotence
Lancet
(1987) - et al.
Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial
J Urol
(1987) - et al.
Impotence
N Engl J Med
(1989)
Cited by (79)
Erectile Dysfunction
2018, Integrative Medicine: Fourth EditionErectile Dysfunction
2012, Integrative Medicine, Third EditionAphrodisiacs from plant and animal sources-A review of current scientific literature
2011, Food Research InternationalCitation Excerpt :Studies on Yohimbine investigated its effects on both psychogenic ED, caused by psychological complications, and organic ED, the inability to achieve or sustain erection due to physiological problems. The effect of Yohimbine on treatment of psychogenic erectile dysfunction has been well studied in randomized placebo-controlled trials, with results confirming its ability to treat erectile dysfunction (Mann et al., 1996; Montorsi et al., 1994; Reid et al., 1987; Vogt et al., 1997). Dosages of 15 mg–30 mg/day yohimbine were administered orally in the studies.
Trazadone associated with SSRIs and SNRIs in depressed patients with anxiety and insomnia
2007, Psiquiatria BiologicaMulti-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
2006, Pharmacology and TherapeuticsCitation Excerpt :As mentioned above, the antagonist properties of mianserin and mirtazapine at α2-adrenergic receptors act in concert with their blockade of 5-HT2A/2C receptors to preserve sexual function in depression, and to oppose its perturbation in patients (both male and female) undergoing therapy with SSRIs (Aizenberg et al., 1997, 1999; Boyarsky et al., 1999; Farah, 1999; Gelenberg et al., 2000b; Waldinger et al., 2003). It is interesting to note that the combination of yohimbine with trazodone (which possesses 5-HT2C antagonist properties) achieved a marked reversal of psychogenic impotence (Montorsi et al., 1994). This finding further underscores interest in multi-target antidepressants combining antagonist properties at α2-adrenergic and 5-HT2A/2C receptors, yet devoid of the anti-histaminergic and anti-muscarinic actions of mirtazapine and mianserin (Section 9.4.2).
Antidepressant medications: A review of the evidence for drug-induced sexual dysfunction
2002, Journal of Affective Disorders